| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60f67cf07e3fdc9c7d98b1c36039ec12 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d256291f0abd0d1f345860b6b7ae4ad6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df8441ad1b39374b77e80e0629904dbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29d5690058ecea043df1039ac8e2d578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5af09aff8ffd22795713d3843e8cee96 |
| publicationDate |
2014-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014028840-A |
| titleOfInvention |
Means and methods for treating neoplastic diseases |
| abstract |
Disclosed is a medication means and method that can retain the biological activity of an administered antibody to the maximum while minimizing undesired adverse side effects of this administration. A binding domain specific to human CD3 and human CD19 is included, and the corresponding heavy chain variable region (VH) and the corresponding light chain variable region (VL) are arranged in the following order from the N-terminus to the C-terminus: VL (CD19) -VH (CD19) -VH (CD3) -VL (CD3), VH (CD19) -VL (CD19) -VH (CD3) -VL (CD3), VH (CD3) -VL (CD3)- VH (CD19) -VL (CD19), or VH (CD3) -VL (CD3) -VL (CD19) -VH (CD19), bispecific single chain antibody constructs from 10 A therapeutic agent administered at a daily dose of 80 μg for at least one week, the daily dose taking at least 6 hours. [Selection figure] None |
| priorityDate |
2005-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |